Intellia Therapeutics, Inc.

LSE:0JBU Stock Report

Market Cap: US$979.9m

Intellia Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:0JBU Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Mar 25SellUS$23,122James BastaIndividual2,572US$8.99
04 Mar 25SellUS$6,104Eliana ClarkIndividual679US$8.99
03 Jan 25SellUS$97,089Eliana ClarkIndividual7,978US$12.18
03 Jan 25SellUS$326,509John LeonardIndividual26,807US$12.18
03 Jan 25SellUS$79,194Derek HicksIndividual6,502US$12.18
03 Jan 25SellUS$86,161James BastaIndividual7,074US$12.18
03 Jan 25SellUS$16,711Michael DubeIndividual1,372US$12.18
03 Jan 25SellUS$109,206Laura Sepp-LorenzinoIndividual8,966US$12.18
03 Jan 25SellUS$116,404David LebwohlIndividual9,557US$12.18
02 Oct 24SellUS$38,248Michael DubeIndividual2,012US$19.01
01 Jul 24SellUS$9,287Eliana ClarkIndividual405US$22.93

Insider Trading Volume

Insider Buying: 0JBU insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0JBU?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,413,1091.36%
General Public2,616,2382.53%
Public Companies3,702,9953.57%
Institutions95,851,05292.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 77.07% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.6%
ARK Investment Management LLC
13,011,015US$123.1m3.79%0.99%
10.4%
The Vanguard Group, Inc.
10,752,031US$101.7m5.51%no data
10.2%
BlackRock, Inc.
10,556,041US$99.9m-2.78%no data
4.35%
State Street Global Advisors, Inc.
4,510,261US$42.7m-13.4%no data
3.65%
Capital Research and Management Company
3,779,424US$35.8m0%no data
3.57%
Regeneron Pharmaceuticals, Inc.
3,702,995US$35.0m0%no data
2.73%
Nikko Asset Management Co., Ltd.
2,825,361US$26.7m-5.59%0.01%
2.66%
Citadel Advisors LLC
2,757,568US$26.1m10.6%0.03%
2.39%
Geode Capital Management, LLC
2,480,173US$23.5m3.81%no data
2.33%
Morgan Stanley, Investment Banking and Brokerage Investments
2,413,435US$22.8m19.7%no data
2.18%
Goldman Sachs Group, Investment Banking and Securities Investments
2,258,423US$21.4m31%0.01%
1.95%
Contrarius Investment Management Ltd.
2,021,040US$19.1m99.7%1.16%
1.93%
Casdin Capital, LLC
2,000,000US$18.9m0%1.6%
1.92%
Two Sigma Investments, LP
1,992,905US$18.9m8.09%0.04%
1.91%
Two Sigma Advisers, LP
1,982,317US$18.8m-0.8%0.04%
1.9%
Dimensional Fund Advisors LP
1,968,166US$18.6m-0.41%no data
1.59%
UBS Asset Management AG
1,648,510US$15.6m-25.9%no data
1.53%
FMR LLC
1,587,171US$15.0m26.8%no data
1.46%
Voloridge Investment Management, LLC
1,515,614US$14.3m-0.75%0.05%
1.46%
Balyasny Asset Management L.P.
1,515,085US$14.3m-34.3%0.04%
1.13%
Morgan Stanley Investment Management Inc.
1,171,367US$11.1m-27.9%0.01%
0.89%
Northern Trust Global Investments
917,761US$8.7m-6.27%no data
0.86%
John Leonard
893,460US$8.5m7.58%no data
0.76%
Stifel Asset Management Corp.
789,662US$7.5m98.5%0.01%
0.75%
Charles Schwab Investment Management, Inc.
780,224US$7.4m-0.92%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 18:50
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intellia Therapeutics, Inc. is covered by 42 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Brian SkorneyBaird
Huidong WangBarclays